X

Trial Profile

A Phase 1 Study of NEU-111 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NEU 111 (Primary)
Indications Inflammation
Focus Adverse reactions; First in man
Sponsors Neuron23

Most Recent Events

24 Feb 2025 Planned End Date changed from 1 Feb 2025 to 22 Feb 2025.
24 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 22 Feb 2025.
03 Dec 2024 According to a Neuron23 media release, the company announced the recent initiation of dosing in a Phase 1 clinical trial of NEU-111 in healthy volunteers.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com